Patents by Inventor Ralf HAUPTMANN

Ralf HAUPTMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for preparing an Fe-tCDTA contrast agent and product obtainable by the method
    Patent number: 11771780
    Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: October 3, 2023
    Assignee: CHARITÉ-UNIVERSITAETSMEDIZIN BERLIN
    Inventors: Eyk Schellenberger, Ralf Hauptmann, Akvile Haeckel, Jing Xie, Joerg Schnorr, Bernd Hamm
  • IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING
    Publication number: 20220331454
    Abstract: The invention provides novel iron(III) complexes with formulae (1) and (2). Furthermore, corresponding ligands with formulae (L1) and (L2) for the production of iron(III) complexes are disclosed.
    Type: Application
    Filed: October 16, 2020
    Publication date: October 20, 2022
    Inventors: Eyk SCHELLENBERGER, Ralf HAUPTMANN, Akvile HÄCKEL, Jing XIE, Jörg SCHNORR, Bernd HAMM
  • METHOD FOR PREPARING AN FE-TCDTA CONTRAST AGENT AND PRODUCT OBTAINABLE BY THE METHOD
    Publication number: 20210260223
    Abstract: A process is provided in which the resulting Fe-tCDTA contrast agent has a reduced osmolality. The process according to the invention comprises the following steps: a) preparing an aqueous solution of tCDTA and FeO(OH), tCDTA and FeO(OH) being present in a molar ratio of from 1:1 to 1:1.4; b) b.1) adjusting a pH of the aqueous solution to between pH 2.5 and pH 4.5 by adding a base, preferably meglumine, and separating the precipitate; or b.2) precipitating the Fe-tCDTA contrast agent from the aqueous solution by adding acetone, separating the precipitate, and preparing an aqueous solution from the precipitate; and c) adjusting a pH of the aqueous solution to between pH 6.5 and pH 8.0 by adding a base, preferably meglumine, and separating the precipitated FeO(OH).
    Type: Application
    Filed: June 6, 2019
    Publication date: August 26, 2021
    Inventors: Eyk Schellenberger, Ralf Hauptmann, Akvile Haeckel, Jing Xie, Joerg Schnorr, Bernd Hamm
  • Drug based on maghemite for simultaneous reduction of gastrointestinal sodium resorption and phosphate resorption
    Patent number: 10632149
    Abstract: The invention includes a substance based on nanocrystalline maghemite having a crystal size of between 0.5 and 4 nm, which is defined by a proportion of divalent iron ions less than five percent by weight of the total iron, and the transport of sodium and simultaneously phosphate in the gastrointestinal wall from the gastrointestinal contents into the bloodstream is reduced and thus can improve the imbalance of electrolyte and water and mineral balances of patients having impaired renal function when used orally in combination with suitable pharmaceutical adjuvants.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 28, 2020
    Assignee: CHARITE-UNIVERSITAETSMEDIZIN BERLIN
    Inventors: Susanne Wagner, Matthias Taupitz, Joerg Schnorr, Monika Ebert, Nicola Stolzenburg, Janna Glaeser, Harald Kratz, Ralf Hauptmann, Janni Breinl, Angela Ariza De Schellenberger, Ines Gemeinhardt
  • DRUG BASED ON MAGHEMITE FOR SIMULTANEOUS REDUCTION OF GASTROINTESTINAL SODIUM RESORPTION AND PHOSPHATE RESORPTION
    Publication number: 20170348351
    Abstract: The invention includes a substance based on nanocrystalline maghemite having a crystal size of between 0.5 and 4 nm, which is defined by a proportion of divalent iron ions less than five percent by weight of the total iron, and the transport of sodium and simultaneously phosphate in the gastrointestinal wall from the gastrointestinal contents into the bloodstream is reduced and thus can improve the imbalance of electrolyte and water and mineral balances of patients having impaired renal function when used orally in combination with suitable pharmaceutical adjuvants.
    Type: Application
    Filed: December 28, 2015
    Publication date: December 7, 2017
    Inventors: Susanne WAGNER, Matthias TAUPITZ, Joerg SCHNORR, Monika EBER, Nicola STOLZENBURG, Janna GLAESER, Harald KRATZ, Ralf HAUPTMANN, Janni BREINL, Angela ARIZA DE SCHELLENBERGER, Ines GEMEINHARDT